Subcutaneous drugs grant a new lease on life to checkpoint inhibitors
The PD-1/PD-L1 inhibitor landscape is at the precipice of change with the approval of Roche’s subcutaneous formulation of Tecentriq.
The PD-1/PD-L1 inhibitor landscape is at the precipice of change with the approval of Roche’s subcutaneous formulation of Tecentriq.
What's Your Reaction?
